A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Presatovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 09 May 2016 Planned End Date changed from 1 Oct 2016 to 1 Apr 2018.
- 09 May 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Mar 2018.
- 27 Jan 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Sep 2016, according to ClinicalTrials.gov record.